[{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"INCB000928","moa":"\nALK2","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"TME Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Emapticap pegol","moa":"aptamers","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"TME Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Gel","sponsorNew":"TME Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TME Pharma \/ Undisclosed"},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"The First Hospital of Jilin University","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"TNP-2092","moa":"Bacterial DNA gyrase | Topoisomerase IV | Bacterial DNA-directed RNA polymerase","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"TenNor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TenNor Therapeutics \/ The First Hospital of Jilin University","highestDevelopmentStatusID":"7","companyTruncated":"TenNor Therapeutics \/ The First Hospital of Jilin University"},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"The First Hospital of Jilin University","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"TNP-2092","moa":"Bacterial DNA gyrase | Topoisomerase IV | Bacterial DNA-directed RNA polymerase","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"TenNor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TenNor Therapeutics \/ The First Hospital of Jilin University","highestDevelopmentStatusID":"7","companyTruncated":"TenNor Therapeutics \/ The First Hospital of Jilin University"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CM355","moa":"CD20\/CD3","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"CM313","moa":"CD-38","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Spark Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"SPK-8016","moa":"Coagulation factor VIII (F8)","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Spark Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spark Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spark Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Bayer AG \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Bayer AG \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Bayer AG \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Bayer AG \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CSL312","moa":"Coagulation factor XII (F12)","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"Shandong Qilu Stem Cells Engineering Co., Ltd.","sponsor":"Shandong Province Third Hospital | Dezhou People's Hospital | Children's Hospital Affiliated to Shandong University | The Second Affiliated Hospital of Shandong First Medical University | Tai\u2019an Central Hospital | Linyi People's Hospital | Rizhao People's","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CHINA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Shandong Qilu Stem Cells Engineering Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shandong Qilu Stem Cells Engineering Co., Ltd. \/ Shandong Province Third Hospital | Dezhou People's Hospital | Children's Hospital Affiliated to Shandong University | The Second Affiliated Hospital of Shandong First Medical University | Tai\u2019an Central Hospital | Linyi People's Hospital | Rizhao People's","highestDevelopmentStatusID":"7","companyTruncated":"Shandong Qilu Stem Cells Engineering Co., Ltd. \/ Shandong Province Third Hospital | Dezhou People's Hospital | Children's Hospital Affiliated to Shandong University | The Second Affiliated Hospital of Shandong First Medical University | Tai\u2019an Central Hospital | Linyi People's Hospital | Rizhao People's"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Evening Primrose Oil","moa":"Erythropoietin receptor","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"UT Southwestern Medical Center \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"Hemab Therapeutics","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2023","type":"Series B Financing","leadProduct":"HMB-001","moa":"Factor VIIa","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Hemab Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0.14000000000000001,"dosageForm":"Capsule","sponsorNew":"Hemab Therapeutics \/ Deep Track Capital","highestDevelopmentStatusID":"7","companyTruncated":"Hemab Therapeutics \/ Deep Track Capital"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Coagulation Factor VIIa","moa":"F7a||Factor VIII","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Catalyst Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Catalyst Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Marzeptacog Alpha","moa":"Factor VIII","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Catalyst Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Catalyst Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Sealantium Medical","sponsor":"Sintesi Research Srl | Home Medics Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"ISRAEL","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Human Fibrinogen","moa":"Fibrinogen","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Sealantium Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Sealantium Medical \/ Sintesi Research Srl | Home Medics Consulting","highestDevelopmentStatusID":"7","companyTruncated":"Sealantium Medical \/ Sintesi Research Srl | Home Medics Consulting"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Gansu Provincial Maternal and Child Health Care Hospital | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Partnership for Microbicides \/ Gansu Provincial Maternal and Child Health Care Hospital | National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"International Partnership for Microbicides \/ Gansu Provincial Maternal and Child Health Care Hospital | National Institutes of Health"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"REGN7257","moa":"IL-2 receptor","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"EC-18","moa":"immunomodulators","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enzychem Lifesciences Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Enzychem Lifesciences Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"COR-001","moa":"Interleukin-6","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"JBI-802","moa":"LSD1\/HDAC6","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jubilant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jubilant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University of Maryland, Baltimore","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"University of Maryland, Baltimore","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Maryland, Baltimore \/ Johnson & Johnson","highestDevelopmentStatusID":"7","companyTruncated":"University of Maryland, Baltimore \/ Johnson & Johnson"},{"orgOrder":0,"company":"Ohio State University Comprehensive Cancer Center","sponsor":"Incyte Corporation | Jazz Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Allogeneic Hematopoietic Stem Cell Transplant","moa":"Progenitor cell","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Ohio State University Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ohio State University Comprehensive Cancer Center \/ Incyte Corporation | Jazz Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Ohio State University Comprehensive Cancer Center \/ Incyte Corporation | Jazz Pharmaceuticals"},{"orgOrder":0,"company":"CellMed AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Allogenic Mesenchymal Cell","moa":"Progenitor cell","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"CellMed AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CellMed AG \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CellMed AG \/ Undisclosed"},{"orgOrder":0,"company":"Prolong Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Anf-Rho","moa":"Rho kinase","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Prolong Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prolong Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Prolong Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"University of Michigan","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Uproleselan","moa":"Selectin E","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Crescent Biopharma \/ University of Michigan","highestDevelopmentStatusID":"7","companyTruncated":"Crescent Biopharma \/ University of Michigan"},{"orgOrder":0,"company":"Yale University","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Camostat","moa":"serine","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ Ono Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Yale University \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"National Heart, Lung, and Blood Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Horse Antithymocyte Globulin","moa":"T cells","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"National Heart, Lung, and Blood Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Heart, Lung, and Blood Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"National Heart, Lung, and Blood Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Alexey Danilov","sponsor":"Gilead Sciences | Oregon Health and Science University","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Entospletinib","moa":"Tyrosine-protein kinase SYK","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Alexey Danilov","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexey Danilov \/ Gilead Sciences | Oregon Health and Science University","highestDevelopmentStatusID":"7","companyTruncated":"Alexey Danilov \/ Gilead Sciences | Oregon Health and Science University"},{"orgOrder":0,"company":"Medgenics Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Autologous Skin Graft","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Medgenics Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Medgenics Medical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Medgenics Medical \/ Undisclosed"},{"orgOrder":0,"company":"Natural Immune Systems Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"Jobelyn","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Natural Immune Systems Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Natural Immune Systems Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Natural Immune Systems Inc \/ Undisclosed"},{"orgOrder":0,"company":"Singapore General Hospital","sponsor":"DSO National Laboratories | Health Sciences Authority, Singapore","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SINGAPORE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Platelet","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Singapore General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Singapore General Hospital \/ DSO National Laboratories | Health Sciences Authority, Singapore","highestDevelopmentStatusID":"7","companyTruncated":"Singapore General Hospital \/ DSO National Laboratories | Health Sciences Authority, Singapore"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TAK-662","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
